Highest-materiality recent filing
Mangoceuticals files lawsuit seeking >$73M against Clarity Ventures; CEO options repriced to $0.45
Filed lawsuit in Texas state court against Clarity Ventures seeking damages exceeding $73M for failure to deliver HIPAA-compliant ERP/eCommerce platform.
Mangoceuticals' MGX-0024 zero respiratory mortality in 29,000-bird trial; 60% H5N1 mortality cut
Three commercial field trials in India (~29,000 broilers) with MGX-0024 drinking water showed zero respiratory-related mortality vs. historical ~50%.
MangoRx's new $99/mo injectable TRT sees 336% MoM sales growth, 54% CAC drop
Month-over-month sales of injectable TRT program increased 336% since mid-December 2025 launch.
Mangoceuticals receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq notice on Feb 4, 2026: bid price below $1.00 for 30 consecutive days.
Up to $100M Solana-focused digital asset treasury strategy launched via subsidiary Mango DAT, LLC.
Mangoceuticals raises $2.5M via registered direct offering and private placement
$2.5M gross proceeds from sale of 1.43M common shares at $1.295 and 500K pre-funded warrants at $1.29499.
Mangoceuticals partners with Lilly and Novo Nordisk for GLP-1 access programs; $99/month membership
Launches MangoRx Direct and PeachesRx Direct providing access to Zepbound (Eli Lilly) and Wegovy (Novo Nordisk) via telehealth.
Mangoceuticals grants 500k shares and 2M options to CEO; CFO and directors each receive 100k shares
CEO Jacob Cohen receives 500,000 common shares as 2025 bonus and options to purchase 2,000,000 shares at $2.30.
Mangoceuticals raises $1.1M via private placement of 709,677 shares at $1.55/share
Sold 709,677 restricted common shares at $1.55 per share to five accredited investors.
Mangoceuticals rescinds IP purchase and consulting pacts, cancels 1.65M shares
On May 22, 2025, entered rescission agreements with ArcStone, Smokeless, and Strategem.
Mangoceuticals settles lawsuit with 62,500 shares, gets $100k loan from CEO trust at 18%
Entered settlement with 1800 Diagonal Lending, issuing 62,500 restricted shares to dismiss lawsuit with prejudice (May 5, 2025).
Acquired IP from Smokeless Technology Corp. for 1,600,000 restricted shares of MGRX common stock and 10% royalty on gross pouch product sales.
Mangoceuticals sells $100K Series B preferred, borrows $500K at 18% from Indigo Capital
Sold 100 shares of Series B Convertible Preferred at $100K; stated value $1,100/share, convertible at $1.50 into up to 73,333 common shares.
Mangoceuticals secures exclusive US/Canada rights to Diabetinol®; 1M shares and royalty
Exclusive rights to Diabetinol® in US & Canada; nutraceutical for blood glucose/HbA1c management.
Stockholders approve Series B conversion price cut to $1.50 and 2022 equity plan expansion
Series B Preferred conversion price reduced to $1.50 (from $2.25); floor price removed; dividend rights eliminated.
Amends $20M patent deal to credit R&D costs; raises $710K via stock sales
Amends Patent Purchase Agreement; cash payments reduced to $306K from $373K as of Dec 31, 2024.
Mangoceuticals converts $150K note into 100K shares; appoints Antonios Isaac as President & Director
Debt conversion with Mill End Capital: $150K promissory note converted to 100K restricted common shares at $1.50/share.
Mangoceuticals subsidiary creates Series A Preferred Stock granting CEO 51% voting control
Series A Preferred Stock of M&P subsidiary gives holders 51% of total vote on all shareholder matters.
Mangoceuticals raises $900k via Series B Preferred and warrants for 1.188M shares
Closed four SPAs from Dec 31, 2024 through Jan 6, 2025, selling 900 shares of Series B Preferred at $1,000 each for $900k total.
Mangoceuticals raises up to $1.25M via Series B Preferred and warrants
Issued 350 shares of Series B Preferred for $350K and warrants for 462K shares at $2.57-$2.71 exercise price.
Acquired mushroom patent WO 2023/086647 from Greenfield Investments for 515,000 restricted shares of common stock.
MangoRx Board initiates strategic alternatives review to maximize shareholder value
Formalized $150K promissory note with CEO's entity Cohen Enterprises at 8% interest, due Jan 2, 2025.
MangoRx faces Eli Lilly lawsuit over alleged copying of weight-loss drugs Zepbound/Mounjaro
Eli Lilly filed a lawsuit claiming MangoRx improperly copied its weight-loss medicines Zepbound and Mounjaro.
Mangoceuticals announces 1-for-15 reverse stock split to meet Nasdaq $1 bid price
Reverse stock split at 1:15 ratio effective October 16, 2024 at 12:01 a.m. ET.
Mangoceuticals issues shares and warrants to consultants, draws $521K from ELOC
Issued 150k shares to Veritas Consulting for $43,155 value; $7.5k/month cash for 3-month consulting.
MangoRx launches oral Semaglutide weight-loss treatment 'Slim' at $299/month
Launched oral Semaglutide ODT compounded with Vitamin B6, branded 'Slim', on MangoRx.com.
Pursuant to the Hammer Amendment, Ms. Hammer’s role with the Company was expanded to include serving as Chief Operating Officer of Mango & Peaches Corp.,
appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.
appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.
Effective on May 1, 2023, the Board of Directors of Mangoceuticals, Inc. (the “ Company ”, “ we ” and “ us ”) appointed Mrs. Amanda Hammer, as the Chief Operating Officer (COO) of the Company.
As a result of such appointment Jonathan Arango, the President, Secretary and member of the Board of Directors of the Company, ceased serving as COO, but will continue serving in his other roles with the Company.
Max materiality 0.85 · Median 0.60 · Most common event other_material